ScreenerHero

PASG Passage Bio, Inc.

NAS · US · Healthcare · Biotechnology · passagebio.com
3.855USD-5.51%Mkt Cap: 12.40M $P/E: —

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD c…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap12.40M USD
Enterprise Value-11.03M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-45.52M USD
Revenue/Share—
Last Price3.855 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees24
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.39
PEG—
EV/EBITDA0.29
EV/Revenue—
P/S—
P/B2.95
EPS (TTM)-11.33
EPS (Forward)-10.39
52W Range
3.2953% of range20.00
52W High20.00 USD
52W Low3.295 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-242.72%
ROA-73.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-31.51M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-119.43%
Net Debt-24.16M USD
Net Debt/EBITDA0.64
Balance Sheet
Debt/Equity1.28
Current Ratio1.22
Quick Ratio1.17
Book Value/Sh1.39 USD
Cash/Share7.51 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJul 14, 2025
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)15.50 USD
Upside (mean)+302.1%
Target Range8.000 USD – 23.00 USD
8.000+302.1% to mean23.00
# Analysts2
Ownership
Shares Out.3.22M
Float3.20M
Insiders7.71%
Institutions46.43%
Short Interest
Short Ratio3.9d
Short % Float3.76%
Short % Out.3.01%
Shares Short97.01K
Short (prev mo.)136.94K
Technical
SMA 504.610 (-16.4%)
SMA 2007.171 (-46.2%)
Beta1.39
S&P 52W Chg16.45%
Avg Vol (30d)26.54K
Avg Vol (10d)17.65K
Technical Indicators
RSI (14)24.7
MACD-0.1736
MACD Signal-0.0714
MACD Hist.-0.1021
BB Upper5.358 USD
BB Middle4.634 USD
BB Lower3.910 USD
BB Width31.24%
ATR (14)0.2831 USD
Vol Ratio (20d)0.45x